WILMINGTON, DEL (July 26, 2004) – AstraZeneca announced the U.S. Food and Drug Administration (FDA) has approved additional efficacy labeling information based on 12-week data for SEROQUEL, a psychotropic medication indicated for the treatment of acute manic episodes associated with bipolar I disorder.
An indication for SEROQUEL was approved in January 2004, as a monotherapy and adjunct therapy with lithium or divalproex, for the short-term treatment of acute manic episodes associated with bipolar I disorder.
AstraZeneca is an international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services.